• Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY;
  • Revenue from Continuing Operations^[1] Reached RMB12.04 Billion, Up 19.7% YoY
• Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; 
  • Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY
• Q1-Q3 Net Profit Attributable to Owners of the Company Reached RMB12.08 Billion^[2], Up 84.8% YoY;
  • Diluted Earnings per Share (EPS) of RMB4.21^[3], Up 87.9% YoY
• Q1-Q3 Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB10.54 Billion, Up 43.4% YoY;
  • Adjusted Non-IFRS Diluted EPS of RMB3.68, Up 46.0% YoY
• Backlog for Continuing Operations Reached RMB59.88 billion as of September 30, 2025, Up 41.2% YoY
• Q1-Q3 Operating Cash Flow Achieved RMB10.87 Billion, Up 35.0% YoY

SHANGHAI, Oct. 26, 2025 /PRNewswire/ — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first three quarters ending September 30, 2025 (“Reporting Period”): 

• For the first three quarters of 2025, total revenue reached RMB32.86 billion, up 18.6% year-over-year. Revenue from Continuing Operations reached RMB32.45 billion, up 22.5% year-over-year.
• Adjusted non-IFRS gross profit reached RMB15.46 billion, with the adjusted non-IFRS gross profit margin up 6.1pts year-over-year to 47.0%.
• Net profit attributable to the owners of the Company was RMB12.08 billion, up 84.8% year-over-year; diluted EPS was RMB4.21, up 87.9% year-over-year.
• Adjusted non-IFRS net profit attributable to the owners of the Company was RMB10.54 billion, up 43.4% year-over-year; adjusted non-IFRS net profit margin up 5.6pts year-over-year to 32.1%; adjusted non-IFRS diluted EPS was RMB3.68, up 46.0% year-over-year.
• With continuous capacity expansion to better meet customer demand, backlog for Continuing Operations reached RMB59.88 billion as of September 30, 2025, up 41.2% year-over-year.
• Operating cash flow climbed 35.0% year-over-year to RMB10.87 billion, driven by business growth, increase in operating efficiency, and continued improvement of financial management capabilities.
• Sustained and steady business growth as a result of our unique, fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. Driven by “follow the molecule” and “win the molecule” strategies, WuXi Chemistry’s small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first three quarters of 2025, a total of 621 new molecules were added to the small molecule Development and Manufacturing (D&M) pipeline. As of September 30, 2025, our small molecule D&M pipeline reached 3,430 molecules, representing an increase of 15 projects in phase III and commercial stages during the first three quarters of 2025.
• Acceleration of global expansion, capacity construction and capability development. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. By the end of 2025, total reactor volume of small molecule APIs is expected to reach over 4,000kL. In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule; the Company’s total reactor volume of Solid Phase Peptide Synthesizers has been increased to more than 100,000L.
• Robust shareholder returns. The Company remains committed to rewarding shareholders and actively supporting the Company’s value. This year, the Company has implemented a total of RMB6.88 billion in cash dividends, share repurchases and cancellations, representing more than 70% of the Company’s 2024 net profit attributable to the owners of the Company. Among these, the Company has distributed a total of RMB4.88 billion in cash dividends, including RMB2.83 billion for the 2024 annual cash dividend, RMB1.01 billion for the 2025 special cash dividend and RMB1.03 billion for the 2025 interim dividend. Meanwhile, the Company also completed the repurchase of RMB2.0 billion worth of A-shares in total, all of which have been cancelled.

2025 Full-Year Outlook

With confidence in customers’ ongoing demand for enabling services, our CRDMO business model and management execution, the Company has further raised its full-year guidance.

The Company expects Continuing Operations revenue to resume double-digit growth in 2025, with its year-over-year growth rate raised to 17-18%, up from the prior 13-17%. As a result, the Company expects full-year total revenue of RMB43.5-44.0 billion, up from the prior RMB42.5-43.5 billion.

As it focuses on the core CRDMO business and continuously improved production and operating efficiency, the Company is confident and expects to further improve the adjusted non-IFRS net profit margin in 2025.

The Company is actively advancing global capacity construction; while due to longer-than-expected settlement cycles of certain projects, capex for 2025 is expected to reach RMB5.5-6.0 billion (adjusted from the prior RMB7.0-8.0 billion). Together with business growth, efficiency improvement, and considering the timing differences in project payments, free cash flow for 2025 is expected to increase from RMB5.0-6.0 billion to RMB8.0-8.5 billion.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, “Reflecting robust customer demand and the strength of our unique CRDMO business model, WuXi AppTec delivered strong double-digit growth in revenue, profit and operating cash flow in the first three quarters of 2025, while our backlog for Continuing Operations reached a record RMB59.9 billion. Based on this momentum, we have further raised our full-year revenue and free cash flow guidance. The strategic divestment of clinical research services enables us to fully focus on our core CRDMO strategy and better meet the evolving needs of our customers. By concentrating on drug discovery, laboratory testing, process development, and manufacturing services, we are accelerating the growth of our global capabilities and capacities, delivering greater value for customers and shareholders, and advancing our vision that ‘every drug can be made and every disease can be treated’.”

Business Performance by Segment

• WuXi Chemistry: CRDMO Business Model Drives Continuous Growth; Q1-Q3 2025 Revenue Up 29.3% YoY, with TIDES Revenue Up 121.1% YoY
  • Q1-Q3 revenue of WuXi Chemistry reached RMB25.98 billion, up 29.3% year-over-year. With continued optimization of production process and improvement in capacity efficiency driven by the growth of late-stage clinical and commercial projects, Q1-Q3 adjusted non-IFRS gross profit margin of WuXi Chemistry steadily improved 5.8pts year-over-year to 51.3%.
  • Small molecule drug discovery service (“R”) continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 430,000 new compounds to customers. In the meantime, 250 molecules were converted from R to D phase in the first three quarters of 2025. Through our “follow-the-customer” and “follow-the-molecule” strategies, we established trusted partnerships with our customers globally, supporting the sustainable growth of our CRDMO business.
  • Small molecule D&M service remains strong.
    1. The small molecule CDMO pipeline continued to expand. Q1-Q3 revenue of small molecule D&M services rose 14.1% year-over-year to RMB14.24 billion. In the first three quarters of 2025, 621 new molecules were added to the small molecule D&M pipeline. As of September 30, 2025, our small molecule D&M pipeline reached 3,430 molecules, including 80 commercial projects, 87 in phase III, 374 in phase II and 2,889 in phase I and pre-clinical stages. This represents an increase of 15 projects in the commercial and phase III stages during the first three quarters of 2025.
    2. We continued to build small molecule capacity. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. The total reactor volume of small molecule APIs is expected to reach over 4,000kL by the end of 2025.
  • TIDES business (oligo and peptides) sustains rapid growth.
    1. With the ramp-up of new capacities released sequentially each quarter last year, Q1-Q3 TIDES revenue grew 121.1% year-over-year to RMB7.84 billion. As of September 30, 2025, TIDES backlog grew 17.1% year-over-year.
    2. TIDES D&M customers grew 12% year-over-year, while the number of TIDES molecules grew 34% year-over-year.
    3. In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule; the Company’s total reactor volume of Solid Phase Peptide Synthesizers has been increased to more than 100,000L.

• WuXi Testing: Drug Safety Evaluation Service & Site Management Organization (SMO) Maintain Leading Positions
  • WuXi Testing revenue reached RMB4.17 billion in Q1-Q3, and Q1-Q3 adjusted non-IFRS gross profit margin was 26.5%.
  • With development of differentiated capabilities and enhanced operational management, Q3 revenue of lab testing services reached RMB1.08 billion, growing 7.2% year-over-year and 7.5% quarter-over-quarter; while its Q3 adjusted non-IFRS gross profit margin continued to improve quarter-over-quarter. Of which, the revenue of drug safety evaluation services grew 5.9% year-over-year and 13.2% quarter-over-quarter.
  • Q1-Q3 revenue of lab testing services grew 2.7% year-over-year to RMB2.96 billion. Due to market impact, its Q1-Q3 adjusted non-IFRS gross profit margin declined as pricing was gradually reflected in revenue along with backlog conversion. Of which, drug safety evaluation services revenue resumed positive year-over-year growth, while maintaining an industry-leading position in the Asia-Pacific region.
  • The Company is committed to actively enabling customers’ global licensing. New modality business continued to develop, while the Company maintained its leading position in areas including nucleic acids, conjugates, mRNA, multispecific antibodies and peptides.
  • The Company continued to advance automation. DMPK successfully launched its proprietary all-in-one compound identification software, enhancing efficiency in spectral interpretation and metabolite identification for nucleic acids and peptides by 83%.
  • The Suzhou facility has successfully passed 4 consecutive FDA on-site inspections.
  • Q1-Q3 revenue for clinical CRO & SMO was down 6.4% year-over-year to RMB1.21 billion due to market pricing impact; of which, SMO revenue was down 0.7% year-over-year as backlog gradually converted into revenue, while maintaining its industry leading position in China.
  • During the first three quarters of 2025, our clinical CRO business supported customers in obtaining 19 IND approvals and submitting for 2 NDA filings; the SMO business supported 75 new drug approvals for customers. The SMO business has supported 331 new drug approvals in total over the past decade, maintaining significant advantages in multiple areas (endocrinology, dermatology, lung cancer and cardiovascular disease, etc.).

• WuXi Biology: Continues to Generate Downstream Opportunities; In Vitro & In Vivo Business Synergies and New Modality Business Drive Growth
  • WuXi Biology follows the science, continuously strengthens drug discovery capabilities in emerging areas and actively grows overseas businesses. It efficiently generates downstream opportunities for CRDMO model by continuously contributing more than 20% of the Company’s new customers.
  • Through cross-regional collaboration, comprehensive platform integration and integrated project transformation, we efficiently enable our customers worldwide. WuXi Biology revenue reached RMB1.95 billion in Q1-Q3 2025, a year-over-year increase of 6.6%.
  • Due to market pricing impact, Q1-Q3 adjusted non-IFRS gross profit margin of WuXi Biology was down 1.0pts to 37.0%. With continuously improved operational efficiency, its Q3 adjusted non-IFRS gross profit margin improved 1.5pts quarter-over-quarter.
  • We accelerated advancements in in vitro integrated screening technologies and continued to improve in vivo pharmacology capabilities, resulting in rapid year-over-year and quarter-over-quarter revenue growth. With its competitive edge continuously strengthened, the non-oncology business has achieved strong revenue growth, becoming an important contributor to business growth.
  • New modality drug discovery services continue to perform well, contributing more than 30% of WuXi Biology’s total revenue.

This release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For additional information, please refer to the WuXi AppTec 2025 Third Quarterly Results Presentation and 2025 Third Quarterly Report disclosed on the Company’s official website, as well as the Company’s disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited website. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

Net profit attributable to the owners of the Company is prepared in accordance with China Accounting Standards for Business Enterprises (CAS), in currency of RMB. Besides, all other financial information disclosed in this press release is prepared in accordance with the International Financial Reporting Standards Accounting Standards (“IFRSs”), in currency of RMB.

The 2025 Third Quarterly Report of the Company has not been audited.

Third Quarter 2025 Results by Segments

Unit: RMB million

First Three Quarters 2025 Results by Segments

Unit: RMB million

Note 1: In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the first three quarters of 2025 or the comparison year as discontinued operations.

Note 2: Any sum of the data above that is inconsistent with the total is due to rounding.

Consolidated Statement of Profit or Loss^[4] – Prepared under IFRSs

Consolidated Statement of Profit or Loss^[5] (continued) – Prepared under IFRSs

Consolidated Statement of Financial Position^[6] – Prepared under IFRSs

Consolidated Statement of Financial Position (continued)^[7]– Prepared under IFRSs

Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company^[8]

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

Forward-Looking Statements

This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor an undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law.

Continuing Operations and Discontinued Operations

In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the first three quarters of 2025 or the comparison year as discontinued operations (“Discontinued Operations”). The remaining operations of the Company will continue to be reported as continuing operations (“Continuing Operations”).

Use of Non-IFRS and Adjusted Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, foreign exchange-related gains or losses, amortization of acquired intangible assets from merger and acquisition, gains or losses from divestiture, restructuring and resource integration initiatives, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRSs.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRSs. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRSs, or as being comparable to results reported or forecasted by other companies.

HONG KONG, Oct. 26, 2025 /PRNewswire/ — As the global shift towards electric mobility reaches a pivotal crossroads, breakthroughs in technology, infrastructure and sustainability are converging to create a landscape rich in both opportunities and challenges. To bring together global expertise and accelerate the transition, the 2025 International Forum on New Journey of Electric Vehicle Revolution was successfully held in Hong Kong today, hosted by The Greater Bay Area Association of Academicians (GBAAA) and co-organised by the International Academicians Science and Technology Innovation Centre and the Research Centre for Electric Vehicles at The Hong Kong Polytechnic University.

The forum, themed “Strengthening Electrification & Advancing Intelligence,” brought together leading scholars, industry pioneers and policy experts from around the world. Discussions centred on three topics — Recent Advances in Electric Mobility, Powertrains, Batteries and Hydrogen, and Electric Vehicles’ Interaction with Power Grids and Clouds. The forum aims to advance from intelligent connected vehicles to intelligent transportation, smart cities, and ultimately an intelligent society — realising the vision that “Mobility is Freedom, Mobility is Happiness. “

At the opening of the forum, Professor Nancy IP, Academician of the Chinese Academy of Sciences, Chair of GBAAA, and President of The Hong Kong University of Science and Technology, delivered the welcome remarks. She noted that Hong Kong exerts unique advantages in promoting electric vehicle technology and industrial collaboration across the Greater Bay Area, and even globally. Professor IP added that GBAAA is proud to provide this opportunity to strengthen electrification, advance intelligence, and build the integrated systems that will truly power the next chapter of the electric vehicle revolution.

In his opening remarks, Dr GE Ming, Acting Permanent Secretary for Innovation, Technology and Industry of the Government of the Hong Kong Special Administrative Region, emphasised that although Hong Kong is not a traditional automotive hub, it has long contributed to advancing electric vehicles through research and innovation. The research teams continue to explore breakthroughs in battery technology, new energy, materials science, and intelligent systems—bringing Hong Kong’s ingenuity to the forefront of EV innovation.

Dr GE further noted that the electric vehicle revolution is a global endeavour — a complex, collaborative undertaking that calls for innovation across technology, policy, infrastructure, markets, and talent. As both an international innovation and technology centre and a leading international financial centre, Hong Kong is well positioned to serve as a bridge that foster collaboration among government, industry, academia, research, investment and applications. Hong Kong aims to help accelerate the new journey of the electric vehicle revolution and contribute to building a greener, smarter, and more sustainable future of mobility.

In his keynote address, Professor CHEN Xuedong, Academician of the Chinese Academy of Engineering and Vice President of China Association for Science and Technology (CAST), remarked that new energy vehicles have become a shared global solution to climate change and sustainable development. He noted that China’s electric vehicle industry has made remarkable strides — expanding its market scale, advancing technological capabilities, and optimising its industrial ecosystem — all of which are injecting fresh momentum into global growth. Looking ahead, Professor CHEN said that CAST will continue to drive progress by formulating clear technological goals and roadmaps, fostering innovation zones for talent, and strengthening platforms for international collaboration. Through interdisciplinary and cross-sector cooperation, these initiatives aim to accelerate industrial innovation. He also expressed his hope that Hong Kong will leverage its institutional and geographical advantages to promote high-quality development of the electric vehicle industry.

At present, the global electric vehicle industry is undergoing a pivotal shift — from policy-driven growth to a dual engine powered by market forces and technological innovation. How to overcome the initial barriers of cost, range, and infrastructure, and move towards a deeper integration with energy, transportation, and urban systems, has become a shared challenge across the industry. Professor C.C. CHAN, Academician of the Chinese Academy of Engineering, Fellow of the Royal Academy of Engineering, Co-Founder of GBAAA, Distinguished Chair Professor at The Hong Kong Polytechnic University, and widely known as the Father of Asian Electric Vehicles, delivered a keynote speech titled “New Journey of Electric Vehicle Revolution.” He outlined a scientific development paradigm of “Electrification + Intelligence + Connectivity,” calling for scientists, engineers, entrepreneurs, and policymakers to collaborate closely and, through continued iteration, jointly seize the opportunities of industrial transformation. He further called for cross-sector partnerships and sustained innovation to drive smart mobility from technological breakthroughs to large-scale, citywide implementation. Professor CHAN also emphasised the need to strengthen international cooperation and secure a strategic position in the next phase of automotive evolution, fostering the healthy and sustainable growth of the global EV ecosystem.

The Forum featured a rich and wide-ranging agenda, bringing together distinguished speakers from academia, industry, and research institutions for keynote speeches and in-depth panel discussions. The impressive line-up of speakers included Mr Sean GREEN, President and CEO of BMW Group Region China; Mr YIN Tongyue, Chair of Chery Automobile; and senior executives from Chongqing Changan Automobile, Dongfeng Motor, and Geely Research Institute, representing the forefront of the automotive industry. From the academic community, Professor James L. KIRTLEY JR., Member of the U.S. National Academy of Engineering, and Professor of the Massachusetts Institute of Technology, and Dr Don TAN, Member of the U.S. National Academy of Engineering and Vice President of IEEE , shared their insights. Also joining were renowned international experts such as Dr Kenji MORITA, Senior Expert of Japan Automobile Research Institute (JARI) and Dr Myron GRAW, Executive Director of Intelligent Production Systems, INC Innovation Centre, who contributed global perspectives on the evolution of electric mobility.

In his closing remarks, Professor Jin-Guang TENG, Academician of the Chinese Academy of Sciences, Vice Chair of GBAAA of Academicians, and President of The Hong Kong Polytechnic University, summarised the key takeaways of the day’s discussions. He noted that, in the face of climate change and global carbon reduction goals, electrification and smart mobility present significant opportunities for Hong Kong and the Greater Bay Area. While Hong Kong boasts world-class research capabilities and access to international capital, there remains a pressing need to strengthen the connection between research, technology transfer, and industrialisation. Leveraging the innovation and technology platforms in the Northern Metropolis, he suggested, could accelerate this process. Professor TENG also called for broader collaboration and greater alignment of standards across sectors to foster a globally connected ecosystem for green and intelligent mobility.

The successful convening of the 2025 International Forum on New Journey of Electric Vehicle Revolution marks a significant milestone in the global industry’s journey towards “Strengthening Electrification & Advancing Intelligence.” GBAAA will continue to leverage its strengths in scientific research and Hong Kong’s international connectivity to foster cross-disciplinary collaboration. At the same time, it will promote science education and public engagement in innovation, supporting collaborative innovation and technology development across the Greater Bay Area. Through these efforts, GBAAA aims to help Hong Kong and the wider region advance towards becoming a world-class innovation and technology centre, contributing to the nation’s scientific and technological progress.

BEIJING, Oct. 26, 2025 /PRNewswire/ — As profound global changes unseen in a century roll on, China remains resolute in managing its own affairs well and expanding high-level opening-up. Guided by the new development philosophy, the country pursues high-quality development and creates new opportunities for the world.

During the 14th Five-Year Plan period (2021-25), China’s GDP has successively surpassed the 110-trillion-yuan ($15.4 trillion), 120-trillion-yuan, and 130-trillion-yuan marks. It is projected to reach 140 trillion yuan in 2025, with a five-year growth increment exceeding 35 trillion yuan, maintaining a contribution rate of about 30 percent to global economic growth and serving as a “certainty oasis.” 

Xi Jinping, general secretary of the Communist Party of China (CPC) Central Committee, pointed out: “In the face of new developments and tasks, we must further deepen reform comprehensively to continue refining institutions and mechanisms in various sectors, so as to help consolidate foundations, leverage strengths, and shore up areas of weakness. This will enable us to better translate our country’s institutional strengths into effective governance.” 

From a global perspective, China’s “scenery is uniquely beautiful,” demonstrating that under the centralized and unified leadership of the CPC Central Committee, it adheres to a people-centered development philosophy and gives full play to its institutional strength like mobilizing resources for major undertakings, carrying through a blueprint to the end, and ensuring the whole country works together – the profound historical, theoretical, and practical logic at play.

‘Carry through a blueprint to the end’

On October 9, China Huaneng Group Co and China National Chemical Corporation (CNCC), the first batch of centrally administrated enterprises relocated to Xiong’an New Area in Hebei Province, officially moved to the area. Settling into their new home in the area, Yang Gaomin, an employee at CNCC, feels a sense of fulfillment in life: parks are just a short walk from home, the bus ride to work takes only 10 minutes, and “skyscrapers are rising everywhere, shops are bustling, and the city is brimming with vitality.” 

Starting from scratch, the “city of the future” has risen from the ground – a vivid embodiment of the principle of “carrying through a blueprint to the end.”

The key to running China’s affairs well lies in the Party. The centralized and unified leadership of the CPC Central Committee is the fundamental guarantee for carrying out economic work well. At critical junctures, it promptly assesses situations and makes decisions, ensuring the Chinese economy navigates the challenges steadily and sails toward prosperity. This has become the broadest consensus of the Party. 

The scientific formulation and consistent implementation of the five-year plans stand as an important piece of experience in the CPC approach to governing the country. It’s also significantly representing the political advantage of socialism with Chinese characteristics.

Five-year plans are not unique to China, nor did China invent them, yet China alone persists in their successive formulation and implementation. They have become a hallmark of China’s socialist modernization drive, deeply embedded in its socialist system.  

While some countries suffer from shortsighted macroeconomic policies and frequent flip-flops, the Party, through five-year plans as a governance approach, has propelled economic, technological, and comprehensive national strength, as well as people’s living standards, to new heights, ushering in a new era of Chinese modernization. 

From a global perspective, one conclusion grows ever clearer: Under the centralized and unified leadership of the CPC Central Committee, China’s consistent development blueprint—with stable expectations, clear pathways, and an open stance—has achieved simultaneous advances in economic scale and quality, providing crucial support for the global economy to navigate uncertainty. 

‘Mobilizing resources for major undertakings’

In the Yangtze River Delta, along both sides of the G60 Expressway, new factories stretch endlessly. Evolving from a single highway into a sci-tech innovation corridor, the delta’s “G60 Hi-tech Corridor” tells a vivid story of innovation. 

Today, the factory clusters along the G60 Expressway are no longer isolated production spaces but integrated chains linking R&D, manufacturing, logistics, and services. The nine cities have joined forces, painting a grand picture of a “sci-tech economy.” By 2024, the nine cities’ combined economic output reached 9 trillion yuan, contributing nearly 2.2 percent to global manufacturing value added, based on manufacturing estimates. 

The shining innovative light of the corridor is a vivid snapshot of fully leveraging the advantages of the new system for pooling resources nationwide to expedite high-level sci-tech self-reliance.

Mobilizing resources ensures focus on priorities – from refining modern industrial systems and tackling major sci-tech projects to building national megaprojects and advancing green development. Since the new era began, we have adhered to coordinating an efficient market and an effective government, effectively organizing endeavors and initiatives, and guided high-quality development to new levels with the new development philosophy. 

Mobilizing resources enables breakthroughs. Since the new era, China has achieved major original breakthroughs in fields like quantum technology, life sciences, materials science, and space science, driving historic accomplishments and transformations in sci-tech. 

On a global scale, China’s institutional strengths in coordinating an efficient market and an effective government and mobilizing resources for major undertakings stand out even more. While some countries remain mired in policy shortsightedness and flip-flops under multiparty systems, China ensures that the whole country works together, mobilizing all sectors’ enthusiasm and steadily advancing along the right path. 

From a global perspective, one conclusion grows ever clearer: By working as one nation and dynamically leveraging the institutional strength of mobilizing resources for major tasks, China mobilizes all sectors’ enthusiasm, propelling its economic ship to brave winds and waves while sailing steadily ahead. 

Modernization of peaceful development

In the golden autumn, across Yan’an, Northwest China’s Shaanxi Province, and its over 3 million mu of orchards, red apples hang sweetly and crisp. A single apple embodies the original aspiration to serve the people, reflecting the struggles of the new era. 

Yan’an was once a deeply impoverished area. When the bugle for the battle against poverty sounded, the apple industry took the lead. Under a series of policy supports, a single apple has linked a complete “people-enriching industry chain,” creating jobs for over 1 million people and benefiting 800,000 farmers. 

General Secretary Xi once pointed out: ” we must always place the people front and center, respond promptly and effectively to public needs and concerns, and work hard to deliver solid results concerning people’s lives, thereby constantly improving people’s living standards and ensuring that more benefits of modernization are shared among all the people in a more equitable way.”

While some countries grapple with rampant gun violence, racial discrimination, and even fail to ensure basic social stability, China steadfastly upholds “reform for people’s well-being and opening-up for common prosperity” as its value compass, delivering a distinctive response. 

Since the new era, over 2,000 reform plans have placed “people” front and center: healthcare reforms have driven centralized drug procurement to lower prices and curb runaway medical costs; education reforms have advanced integrated urban-rural compulsory education for more equitable high-quality resources; pension service reforms have expanded inclusive supply to address aging society needs.

By advancing a community with a shared future for mankind and proposing four global initiatives, encompassing global development, security, civilization and governance, China demonstrates its responsibility as a major country through concrete actions. In agriculture, it aids developing nations in boosting grain yields via tech cooperation and shares poverty alleviation experience; in energy, its photovoltaic and wind power technologies are exported to multiple countries, facilitating local energy transitions. This “teaching to fish” approach not only elevates development levels in those nations but also creates jobs and improves livelihoods. 

From a global perspective, one conclusion grows ever clearer: Development is for the people and by the people and that its fruits are shared by the people. China steadfastly upholds a people-centered development philosophy, standing firmly on the right side of history and human civilization’s progress. It advances a world of lasting peace, universal security, shared prosperity, openness and inclusiveness, and clean beauty, following the righteous path of humanity. 

China’s practice proves: Socialism with Chinese characteristics is vibrant and full of vitality, anchoring its course with scientific blueprints, igniting momentum through reform and opening-up, and taking improving people’s lives and well-being as the starting and ending point of development.

This system excels at both stimulating endogenous drive and integrating global resources; it emphasizes continuity in strategic planning while sustaining innovative vitality in keeping with the times. This is not only the solid foundation for China’s high-quality development but also a major contribution to the progress of human civilization. 

TORONTO, Oct. 26, 2025 /PRNewswire/ — Visionary Holdings Inc. (Nasdaq: GV) (“Visionary” or the “Company”), a private education service provider integrating technology and innovation, today announced that on August 5, 2025, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its delay in filing its Annual Report on Form 20-F for the fiscal year ended March 31, 2025 (the “Form 20-F”).

The Nasdaq letter has no immediate effect on the listing or trading of the Company’s common shares on the Nasdaq Capital Market. In accordance with Nasdaq rules, the Company was provided 60 calendar days to submit a plan to regain compliance. The Company submitted its compliance plan on October 6, 2025, and is awaiting Nasdaq’s review.

Visionary is working diligently with its independent auditor to complete the audit process and file the Form 20-F as promptly as possible. The Company remains committed to full compliance with its reporting obligations and to maintaining its listing on Nasdaq.

About Visionary Holdings Inc.

Visionary Holdings Inc. is a private education service provider headquartered in Markham, Ontario, Canada. The Company operates through its subsidiaries in the private and public education sectors, delivering quality academic programs supported by technology-driven platforms to both local and international students.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the Company’s plans to regain compliance with Nasdaq’s continued listing requirements and the anticipated timing of its SEC filings. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. The Company does not undertake any obligation to update any forward-looking statement, except as required by law.